The Phage Therapy Market continues to face regulatory and clinical-development challenges. Because phages are biological entities with highly specific characteristics, establishing consistent manufacturing standards and demonstrating safety and efficacy can be complex.

Clinical trials are increasingly important for generating evidence regarding dosing, delivery methods, safety, and therapeutic effectiveness. Greater regulatory clarity could encourage pharmaceutical and biotechnology companies to increase investment in phage-based treatments.

Collaborations among universities, hospitals, biotechnology companies, and government research organizations are helping advance clinical research and develop standardized approaches.